Real-World Treatment Patterns in Patients With Metastatic Castration-Resistant Prostate Cancer in Greece: The PROSPECT Study

• Published in: Clinical genitourinary cancer Vol. 22; no. 6; p. 102170
• Main Authors: Liontos, M., Bournakis, E., Bournakis, A., Kostouros, E., Zolota, V., Papatheodoridi, A.P., Karalis, K., Kyriazoglou, A., Zakopoulou, R., Vasili, E., Tzovaras, A., Dimitriadis, I., Emmanouil, G., Mauri, D., Christodoulou, C., Tsiatas, M., Zagouri, F., Bamias, A.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2024
• Subjects: Guidelines; mCRPC chemotherapy; Novel hormonal agents; Prostatic neoplasms; Therapeutic strategy; Prostatic neoplasms; mCRPC chemotherapy; Novel hormonal agents; Therapeutic strategy; Guidelines
• ISSN: 1558-7673; 1938-0682; 1938-0682
• DOI: 10.1016/j.clgc.2024.102170

•Metastatic castration resistant prostate cancer (mCRPC) treatment has changed dramatically since the introduction of novel hormonal agents (NHAs) but real-world data are lacking in Greece.•The PROSPECT study, a chart review of 149 patients with mCRPC was conducted to capture real-world treatment in mCRPC patients who initiated first line (1L) systemic therapy with chemotherapy or NHAs in Greece, since January 2019.•Most patients in PROSPECT were treated with 1L NHAs, with a longer benefit on treatment duration of NHAs at 1L than chemotherapy, opposite to the pattern in subsequent lines of treatment. Real-world data on management of metastatic castration resistant prostate cancer (mCRPC) with novel therapies is sparse. The aim of this study was to capture real-world management strategies in patients with mCRPC who initiated first line (1L) systemic therapy with chemotherapy or novel hormonal agents (NHAs) in Greece and describe the therapeutic sequencing strategy among patients who advanced to 2L and 3L treatment. In this noninterventional, multicentre, retrospective study (PROSPECT), a medical chart review of 149 patients with mCRPC who initiated 1L systemic therapy with chemotherapy or NHAs in 7 major anticancer hospital clinics, from public, academic, and private sectors in Greece was conducted. All endpoints were descriptively analysed. Kaplan–Meier was used for time-to-event outcomes. At 1L (N = 149), most (78.5%) patients received NHAs; enzalutamide (52.3%), and abiraterone (26.2%). At 2L (N = 68), most (72.1%) patients received chemotherapy, most frequently docetaxel (50.0% of all patients). At 3L (N = 32), 56.3% and 31.3% of patients received chemotherapy and NHAs, respectively. Regarding treatment sequencing from 1L→2L (N = 68), most patients (55.9%) advanced from NHA→chemotherapy. Regarding treatment sequencing from 1L→2L→3L (N = 32), 34.4% advanced from NHAs→chemotherapy→chemotherapy and 31.3% from NHAs→chemotherapy→NHA. Estimated median times spent on treatment at 1L, 2L, and 3L were 9.8, 4.4, and 3.7 months, respectively. Most patients were treated with 1L NHAs, in accordance to established guidelines (which suggest both NHA and chemo as preferred 1st line options). There appeared to be a longer time on treatment of NHAs at 1L than chemotherapy, suggesting an unmet need for treatment optimisation/recommendations for 2L and 3L treatment in mCRPC. PROSPECT captured real-world treatment in patients with metastatic castration resistant prostate cancer (mCRPC) who initiated first line (1L) systemic therapy with chemotherapy or novel hormonal agents (NHAs) in Greece. A chart review of 149 patients with mCRPC was conducted. Most patients were treated with 1L NHAs, with a longer benefit (expressed as time on treatment) of NHAs at 1L.